Friday, 26 February 2021

COMPANY RESULTS

China Sunsine Chemical (CSSC SP)

2H20: Profitability Ramping Up From Increased Capacity

Sunsine saw a good 2H20, with net profit of Rmb136.4m (+11% yoy) bringing full-year earnings to Rmb218.8m (-44%), 7% higher than our estimate. This was helped mainly by increased capacity and uptake due to elevated demand for vehicle tyres in China. Past investments to raise production levels are now bearing fruit, as demand from new vehicle sales in China see uplift from the improving economy. Maintain BUY with target price of S\$0.58.

2H20 RESULTS

Year to 31 Dec (Rmbm)	2H20	2H19	yoy % chg	2020	2019	yoy % chg
Revenue	1,291.1	1,278.0	1.0	2,333.7	2,691.6	(13.3)
Gross profit	358.4	292.8	22.4	600.3	780.8	(23.1)
Gross margin (%)	27.8	22.9	+2.1ppt	25.7	29.0	(3.3ppt)
Net profit	136.4	123.0	10.9	218.8	388.9	(43.9)
Net margin (%)	10.6	9.6	+1.0ppt	9.4	14.4	(5.0ppt)

Source: Sunsine, UOB Kay Hian

RESULTS

- Positive 2H20 results reflect strong demand. China Sunsine Chemical's (Sunsine) 2H20 net profit rose 11% yoy to Rmb136.4m, as revenue grew to Rmb1,291m (+1%) mainly due to record sales volume of 93,556 tonnes (+9.6%), which helped offset the slip in ASPs (-9%) of rubber accelerators. Bottom line benefitted from the expansion of gross profit margin to 27.8% (2H19: 22.9%, 1H20: 23.2%), as well as tight cost control measures. This brought 2020 net profit to Rmb218.8m (-43.9%), 7% above our estimate. The final DPS of 1 S cent was kept.
- Gaining from higher capacity and elevated ASPs. The good set of results was attributed to management's perseverance with continued investments to expand capacity over the past few years, despite the downward trend in rubber accelerator prices. The move is now paying off, with market share for Sunsine more entrenched, alongside rising demand for new vehicles in China. Furthermore, ASP of rubber accelerators, the main earnings driver for Sunsine, has continued to gain ground, in tandem with aniline, the major feedstock for rubber accelerators, due to higher crude oil prices. Average price of aniline has risen an estimated 17% qtd as at 25 Feb 21 to Rmb8,372/tonne, a 29% sequential increase over the 4Q20 average.
- Good proxy to recovering China auto sector. Sunsine derives the bulk of sales from China (2020: 69%, 2019: 61%), which has been strengthening since Mar 20. The Chinese economy is seeing robust growth due to government stimulus measures.

KEY FINANCIALS

Year to 31 Dec (Rmbm)	2019	2020	2021F	2022F	2023F
Net turnover	2,691.7	2,333.7	3,812.5	4,185.9	4,623.3
EBITDA	565.0	422.3	487.5	732.2	658.3
Operating profit	453.1	301.8	357.6	569.0	508.4
Net profit (rep./act.)	388.9	218.8	299.3	476.3	425.6
Net profit (adj.)	388.9	218.8	299.3	476.3	425.6
EPS (Fen)	39.9	22.5	30.8	49.1	43.8
PE (x)	6.0	10.6	7.8	4.9	5.5
P/B (x)	0.9	0.9	8.0	0.7	0.6
EV/EBITDA (x)	2.0	2.7	2.3	1.6	1.7
Dividend yield (%)	2.1	2.1	2.4	4.0	3.5
Net margin (%)	14.4	9.4	7.9	11.4	9.2
Net debt/(cash) to equity (%)	(50.0)	(48.7)	(39.9)	(45.5)	(50.4)
Interest cover (x)	1,184.5	324.8	n.a.	n.a.	n.a.
ROE (%)	15.9	8.3	10.5	15.0	12.0
Consensus net profit	-	202.0	277.7	324.0	-
UOBKH/Consensus (x)	-	-	1.08	1.47	

Source: Sunsine, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$0.49
Target Price	S\$0.58
Upside	+18.4%

COMPANY DESCRIPTION

Sunsine produces rubber chemicals, primarily rubber accelerators and other related rubber chemicals such as anti-scorching agents.

STOCK DATA

GICS sector	Materials
Bloomberg ticker:	CSSC SP
Shares issued (m):	970.7
Market cap (S\$m):	475.7
Market cap (US\$m):	361.1
3-mth avg daily t'over (US\$m):	0.3

Price Performance (%)

52-week hig	gh/low		S\$ 0.54	I/S\$ 0.27
1mth	3mth	6mth	1yr	YTD
3.2	3.2	36.1	11.4	(1.0)
Major Sha	areholders			%
Success Mo	ore Group			59.7
(HoldCo for	Executive C	hairman Xu	Cheng Qiu))

FY21 NAV/Share (Rmb)	3.06
FY21 Net Cash/Share (Rmb)	1.22

PRICE CHART



Source: Bloomberg

ANALYST(S)

Clement Ho +65 6590 6630

clementho@uobkayhian.com



STOCK IMPACT

• Vehicle population growth outweighs global auto chip shortage. On 16 Feb 21, IHS Markit cited that nearly 1m vehicles worldwide will experience production delays in 1Q21 due to a chip shortage, vs its previous estimate of 672,000 units. Having said that, IHS Markit is maintaining its forecast for 2021 global light vehicle sales at 84.6m units (+10.6%), as it expects the industry to recover later in the year. Historically, 30% of the tyre market is driven by new vehicle sales, while 70% comprises replacement tyres. Hence, overall demand is driven by the total vehicle population, rather than vehicle sales. We believe the tyre industry is expected to return to normalcy in 2021 as traffic volume returns to prepandemic levels. Furthermore, as international borders remain shut, a shift towards domestic tourism could spur inter-city/state travel by car, thereby encouraging further demand for tyres.

EARNINGS REVISION/RISK

• Our 2020-21 revenue estimates remain unchanged

VALUATION/RECOMMENDATION

• Maintain BUY with an unchanged target price of \$\$0.58. We kept our valuation peg at 3.5x EV/EBITDA, +1SD of its 5-year average. The target price implies a 2021F PE of 9.6x and ex-cash of 4.1x. This represents a steep discount to larger peers, which are trading at 7.7x forward EV/EBITDA and 15.3x 2021F PE.

SHARE PRICE CATALYST

- · Higher ASPs for rubber accelerators.
- · Higher-than-expected utilisation rates.

PLANNED CAPACITY EXPANSION

Product	Current capacity (ton)	Expansion (ton)	% increase	New capacity (ton)	Completion date	Commercial Production
Rubber Accelerators	117,000					
Insoluble Sulphur	30,000	30,000	+100	60,000	Recently-complete	2H21
Anti-oxidant	45,000	30,000	+67	75,000	1H21	2H21
Total	192,000	60,000		252,000		

Source: Sunsine, UOB Kay Hian

PEER COMPARISON

Company	Bloomberg	Trading	Price @	Market		PE			P/B		E	V/EBITD	Α	Net	ROE
	Ticker	Curr	25 Feb 21	Cap	2019	2020F	2021F	Curr	2020F	2021F	2019	2020F	2021F	Gearing	2020F
			(Icy)	(US\$m)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(%)	(%)
China Sunsine	CSSC SP	S\$	0.490	353	6.2	11.8	8.1	0.9	0.9	0.8	2.0	3.4	2.6	(50.0)	7.5
Shandong Yanggu Huatai	300121 CH	Rmb	14.05	3,888	40.6	27.0	17.5	3.3	n.a.	n.a.	n.a.	n.a.	n.a.	(5.5)	12.9
Lanxess AG	LXS GR	US\$	62.64	4,041	6.0	20.2	15.5	1.7	1.6	1.5	9.3	8.3	6.9	66.5	8.0
Eastman Chemical	AKE FP	US\$	113.37	11,361	18.6	14.6	13.5	2.6	2.3	2.2	10.1	9.8	9.2	85.7	16.1
Arkema SA	AKE FP	EUR	90.26	5,109	18.9	18.0	14.8	1.5	1.3	1.2	7.7	7.7	7.1	30.6	7.4
Global average					21.0	20.0	15.3	2.3	1.7	1.6	9.0	8.6	7.7	44.3	11.1

Source: Bloomberg, UOB Kay Hian



Friday, 26 February 2021

PROFIT & LOSS					BALANCE SHEET				
Year to 31 Dec (Rmbm)	2020	2021F	2022F	2023F	Year to 31 Dec (Rmbm)	2020	2021F	2022F	2023F
Net turnover	2,333.7	3,812.5	4,185.9	4,623.3	Fixed assets	864.6	939.6	916.4	826.5
EBITDA	422.3	487.5	732.2	658.3	Other LT assets	68.3	68.3	68.3	68.3
Deprec. & amort.	120.5	130.0	163.3	149.9	Cash/ST investment	1,326.2	1,185.2	1,542.0	1,876.9
EBIT	301.8	357.6	569.0	508.4	Other current assets	913.0	1,319.3	1,515.8	1,694.3
Associate contributions	0.0	0.0	0.0	0.0	Total assets	3,172.1	3,512.5	4,042.5	4,466.0
Net interest income/(expense)	(1.3)	0.0	0.0	0.0	ST debt	0.0	0.0	0.0	0.0
Pre-tax profit	300.5	357.6	569.0	508.4	Other current liabilities	451.4	537.4	645.6	738.3
Tax	(81.7)	(58.3)	(92.7)	(82.9)	LT debt	0.0	0.0	0.0	0.0
Minorities	0.0	0.0	0.0	0.0	Other LT liabilities	0.0	4.3	6.4	4.1
Net profit	218.8	299.3	476.3	425.6	Shareholders' equity	2,720.7	2,970.7	3,390.6	3,723.7
Net profit (adj.)	218.8	299.3	476.3	425.6	Minority interest	0.0	0.0	0.0	0.0
					Total liabilities & equity	3,172.1	3,512.5	4,042.5	4,466.0
0401151014					VEV METRICS				
CASH FLOW					KEY METRICS	2020	20215	20225	20225
Year to 31 Dec (Rmbm)	2020	2021F	2022F	2023F	Year to 31 Dec (%)	2020	2021F	2022F	2023F
Operating	426.9	113.3	553.1	487.5	Profitability				
Pre-tax profit	300.5	357.6	569.0	508.4	EBITDA margin	18.1	12.8	17.5	14.2
Tax	(63.4)	(70.3)	(75.1)	(87.9)	Pre-tax margin	12.9	9.4	13.6	11.0
Deprec. & amort.	120.5	130.0	163.3	149.9	Net margin	9.4	7.9	11.4	9.2
Working capital changes	103.2	(304.0)	(104.0)	(83.0)	ROA	7.2	9.0	12.6	10.0
Non-cash items	(33.9)	0.0	0.0	0.0	ROE	8.3	10.5	15.0	12.0
Investing	(239.6)	(205.0)	(140.0)	(60.0)					
Capex (growth)	(279.3)	(265.0)	(200.0)	(120.0)	Growth				
Proceeds from sale of assets	60.0	60.0	60.0	60.0	Turnover	(13.3)	63.4	9.8	10.5
Others	(20.3)	0.0	0.0	0.0	EBITDA	(25.3)	15.4	50.2	(10.1)
Financing	(99.7)	(49.3)	(56.4)	(92.5)	Pre-tax profit	(33.6)	19.0	59.1	(10.6)
Dividend payments	(49.3)	(49.3)	(56.4)	(92.5)	Net profit	(43.7)	36.8	59.1	(10.6)
Issue of shares	0.0	0.0	0.0	0.0	Net profit (adj.)	(43.7)	36.8	59.1	(10.6)
Loan repayment	0.0	0.0	0.0	0.0	EPS	(43.7)	36.8	59.1	(10.6)
Others/interest paid	(50.4)	0.0	0.0	0.0	EFS	(43.5)	30.8	59.1	(10.6)
Net cash inflow (outflow)	87.6	(141.0)	356.8	334.9					
Beginning cash & cash equivalent	1,279.9	1,326.2	1,185.2	1,542.0	Leverage				
Changes due to forex impact	(41.3)	0.0	0.0	0.0	Debt to total capital	0.0	0.0	0.0	0.0
Ending cash & cash equivalent	1,326.2	1,185.2	1,542.0	1,876.9	Debt to equity	0.0	0.0	0.0	0.0
					Net debt/(cash) to equity	(48.7)	(39.9)	(45.5)	(50.4)
					Interest cover (x)	324.8	n.a.	n.a.	n.a.



Friday, 26 February 2021

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.





Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

ollowing table.	
General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United	
Ullited	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning
Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in
Kingdom	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
Kingdom United	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients. This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.

Copyright 2021, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W